Kainos Medicine Inc (284620) - Total Assets
Based on the latest financial reports, Kainos Medicine Inc (284620) holds total assets worth ₩11.62 Billion KRW (≈ $7.87 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 284620 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Kainos Medicine Inc - Total Assets Trend (2017–2024)
This chart illustrates how Kainos Medicine Inc's total assets have evolved over time, based on quarterly financial data. See 284620 net asset value for net asset value and shareholders' equity analysis.
Kainos Medicine Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Kainos Medicine Inc's total assets of ₩11.62 Billion consist of 42.9% current assets and 57.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩3.83 Billion | 35.7% |
| Accounts Receivable | ₩256.84 Million | 2.4% |
| Inventory | ₩0.00 | 0.0% |
| Property, Plant & Equipment | ₩602.75 Million | 5.6% |
| Intangible Assets | ₩501.61 Million | 4.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Kainos Medicine Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Kainos Medicine Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kainos Medicine Inc's current assets represent 42.9% of total assets in 2024, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 35.7% of total assets in 2024, down from 100.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is cash and equivalents at 35.7% of total assets.
Kainos Medicine Inc Competitors by Total Assets
Key competitors of Kainos Medicine Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Kainos Medicine Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.72 | 2.63 | 88.58 |
| Quick Ratio | 1.72 | 2.63 | 88.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩2.98 Billion | ₩8.37 Billion | ₩28.02 Billion |
Kainos Medicine Inc - Advanced Valuation Insights
This section examines the relationship between Kainos Medicine Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.62 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -48.8% |
| Total Assets | ₩10.74 Billion |
| Market Capitalization | $24.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kainos Medicine Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kainos Medicine Inc's assets decreased by 48.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kainos Medicine Inc (2017–2024)
The table below shows the annual total assets of Kainos Medicine Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩10.74 Billion ≈ $7.28 Million |
-48.81% |
| 2023-12-31 | ₩20.99 Billion ≈ $14.22 Million |
-46.17% |
| 2022-12-31 | ₩38.98 Billion ≈ $26.42 Million |
-7.09% |
| 2021-12-31 | ₩41.96 Billion ≈ $28.43 Million |
+20.64% |
| 2020-12-31 | ₩34.78 Billion ≈ $23.57 Million |
+225.11% |
| 2019-12-31 | ₩10.70 Billion ≈ $7.25 Million |
+0.92% |
| 2018-12-31 | ₩10.60 Billion ≈ $7.18 Million |
+526.90% |
| 2017-12-31 | ₩1.69 Billion ≈ $1.15 Million |
-- |
About Kainos Medicine Inc
Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to tre… Read more